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Abstract
Alveolar echinococcosis (AE) is caused by infection with the larval stage of the tapeworm
Echinococcus multilocularis. An increasing understanding of immunological events that ac-
count for the metacestode survival in human and murine AE infection prompted us to under-
take explorative experiments tackling the potential of novel preventive and/or
immunotherapeutic measures. In this study, the immunoprotective and immunotherapeutic
ability of recombinant EmP29 antigen (rEmP29) was assessed in mice that were intraperito-
neally infected with E.multilocularismetacestodes. For vaccination, three intraperitoneal in-
jections with 20μg rEmP29 emulsified in saponin adjuvants were applied over 6 weeks. 2
weeks after the last boost, mice were infected, and at 90 days post-infection, rEmP29-vacci-
nated mice exhibited a median parasite weight that was reduced by 75% and 59% when
compared to NaCl- or saponin–treated control mice, respectively. For immunotherapeutical
application, the rEmP29 (20μg) vaccine was administered to experimentally infected mice,
starting at 1 month post-infection, three times with 2 weeks intervals. Mice undergoing
rEmP29 immunotherapy exhibited a median parasite load that was reduced by 53% and
49% when compared to NaCl- and saponin–treated control mice, respectively. Upon analy-
sis of spleen cells, both, vaccination and treatment with rEmP29, resulted in low ratios of
Th2/Th1 (IL-4/IFN-γ) cytokine mRNA and low levels of mRNA coding for IL-10 and IL-2.
These results suggest that reduction of the immunosuppressive environment takes place in
vaccinated as well as immunotreated mice, and a shift towards a Th1 type of immune re-
sponse may be responsible for the observed increased restriction of parasite growth. The
present study provides the first evidence that active immunotherapy may present a sustain-
able route for the control of AE.
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Author Summary
Current medical management of AE that relies on surgery and continuous benzimidazole
administration is of limited effectiveness. Therefore, alternative preventive and therapeutic
tools need to be explored. Here, we demonstrate that vaccination with recombinant anti-
gen EmP29 (rEmP29), prior or after secondary infection of BALB/c mice, resulted in a sig-
nificant reduction of the median parasite weight when compared to different control
groups. We then characterized the transcription level of splenic IL-4 and IFN-γ cytokines
as hallmarks for AE-anti-protective humoral immune reaction (Th2) and for AE-effective
(restrictive) cellular response (Th1), respectively. Results revealed that vaccinated mice in
pre- or post-infection situation exhibited the lowest IL-4/IFN-γmRNA ratios. In addition,
those groups showed also significantly low levels of IL-10-encoding mRNA coding (im-
munosuppressive cytokine), as well as IL-2. These findings suggest that reduction of para-
site load in rEmP29-vaccinated mice (in pre- or post-infection status) might be triggered
by a decline of the immunosuppressive environment and a change of the host immune re-
action towards a Th1-re-oriented cell-mediated immune defense. A similar non-specific
effect appears also to be yielded by the immunostimulating adjuvants. This study provides
the first insight into the potential benefits of antigen-specific immunotherapy as new treat-
ment option of AE.
Introduction
Alveolar echincoccosis (AE), caused by the metacestode larval stage of the fox tapeworm Echi-
nococcus multilocularis, is one of the most severe helminthic diseases worldwide. Human AE
affects the liver in more than 98% of the cases [1,2], and metacestodes grow and proliferate
continuously and infiltratively, forming hepatic lesions that consist of parasite tissue, which is
intermingled with host connective tissue and immune cells. Development of metacestodes af-
fects liver homeostasis and causes irreversible granulomatous liver fibrosis [3–9]. Similar to
malignant tumours, metastasis formation into other organs can take place at a later stage of in-
fection [10].
Radical surgical removal of hepatic lesions is the optimal treatment option, but is feasible in
only about 30% of the patients [11]. In advanced stages of AE, surgery is often incomplete due
to the diffuse infiltration of metacestode tissue into non-resectable structures or sites [12].
The currently available chemotherapy is based on benzimidazole derivatives only, i.e. alben-
dazole (ABZ) and mebendazole (MBZ) that target E.multilocularis β-tubulins [13]. However,
despite that benzimidazole-based therapy has clearly increased the life expectancy of affected
patients [12,14], its mode of action remains parasitostatic rather than parasitocidal [15]. In
vitro studies have shown that ABZ has only restricted parasitocidial activity on E.multilocularis
metacestodes [16,17]. Recently, it has been shown that stem cells of the E.multilocularis larval
are expressing a particular β-tubulin isoform that is resistant to ABZ [18], which may partially
explain the limited effectiveness of ABZ in the complete killing of the parasite [19,20].
From the immunological perspective, modulatory effects of ABZ on the host immune sys-
tem has not yet been investigated. Thus, it may be that ABZ contributes to an increase of the
anti-AE immune response [21]. For AE-patients who do not respond to or do not tolerate the
benzimidazoles, no alternative drugs are available so far [22]. These limitations of the presently
widely applied anti-AE chemotherapy have called for new or alternative or complementary or
supportive therapy options, such as immunotherapy (e.g. complementary to chemotherapy).
rEmP29 for Prevention and Immunotherapy of AE
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Because of the high clinical and economic impact of human AE [23] on each patient, the de-
velopment of protective and effective vaccines as a preventive measure against infection may
represent an attractive alternative strategy. Vaccine candidates for inducing preventive protec-
tive immunity have been described so far, including e.g. recombinant Em 14-3-3 antigen that
protects mice by 97% against E.multilocularis egg infection (primary AE) but not against chal-
lenge with E.multilocularismetacestodes (secondary AE) [24,25]. EG95 is an E. granulosus an-
tigen that exhibited high-level protection against egg infection in sheep [26,27]. Immunization
of mice with the homologous E.multilocularis EM95 antigen resulted in protection rates rang-
ing between 78.5 and 82.9% [27] which was lower than that obtained using the EG95 antigen
in sheep [26,28]. Recently, seven members of a tetraspanin transmembrane protein family
(TSP1 to TSP7) have been shown to exhibit varying protective effects against primary AE. In
infected BALB/c mice [29], the highest and lowest rates of lesion reduction were 87.5% and
37.6%, achieved by vaccination with TSP1 and TSP7, respectively [29,30].
The survival strategy of E.multilocularis is fundamentally based on its ability to induce an-
ergy / immune tolerance in the host, by exerting potent and selective immunomodulatory ac-
tivity [2]. The infection with E.multilocularis triggers an immune response that is
characterized by an increasing imbalance between an initial rather cellular (Th1) and a subse-
quently prevailing humoral (Th2) immune response [2,3]. In the experimental mouse model,
during the initiation of the infection, (early stage AE) both Th1 (IFN-γ) and Th2 (IL-4) related
cytokines are present; but an initial dominance by Th1 cytokines and chemokines has been evi-
denced [5,6]. Subsequently (middle stage), an increase of mRNA levels of IL-4, IL-5, CCL8,
CCL12, and CCL17 (Th2 cell-associated cytokines and related chemokines) is developing [6].
An increasing anergic immune status is evolving during late stage of infection, with an increase
of Th2-oriented cytokine patterns, and an increase of immune-down regulating processes
modulated by Tregs [6,7]. High transcription levels of IL-10 and TGF-β go in line with this
anergic late-phase AE immune-status [3]. Indeed, the current evidence suggests that protection
against E.multilocularis infection is basically associated with the maintenance of a Th1-or-
iented cellular immune response, while an increasingly dominating Th2 profile has been asso-
ciated with a rather progressive form of AE in humans [31,32], although full metacestode
proliferation capacity only occurs when cell-mediated immunity completely fails such as expe-
rienced with AIDS [33]. In a similar context, it has been recently shown that individuals under
immunosuppressive therapy for cancers, autoimmune diseases or subsequent to liver-trans-
plantation are at significant risk for E.multilocularis infection associated with a delayed diag-
nosis. In those patients, progression of AE occurs faster than in non- immunocompromised
patients [34]. It has been suggested that E.multilocularis actively governs the immunological
orientation of the host through up-regulation of immunosuppressive cytokines, mainly IL-10
[35] and TGF-β [7,36]. This may occur via metabolites, and immunomodulatory proteins such
as EmTIP secreted by E.multilocularis during the very early stage of metacestode development
[37] may accordingly be key protagonists. The laminated layer (LL) represents the most outer
component of the E.multilocularis larvae, and LL-associated carbohydrate antigens such as
Em2(G11) and Em492 [31,38,39] were shown to exhibit suppressive effects on concanavalin A
—mediated proliferation of spleen cells from E.multilocularis-infected mice. Thus components
of the LL could be involved in modulating the Th1/Th2 balance by driving it from a Th1-domi-
nation to a rather Th2-oriented control characterized by anergy promoted via Tregs and other
immunomodulating parameters.
The working hypothesis for the present study was based on the work published by Harraga
et al. [40] that a support of the host to maintain, or re-orientate, its immune response at a
Th1-level may contribute to restrict or inhibit metacestode growth. Immunotherapy can either
be active (or antigen-specific) or passive (non-specific). In non-specific immunotherapy,
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immune molecules are administrated to infected individuals to modulate an existing, but non-
protective, immunity towards an adequate and effective response. Cytokines that promote dif-
ferentiation of Th1 cells such as IL-12 [41] and IFN-α-2a [40,42] have been assessed for passive
immunotherapy of AE in experimentally infected mice. Passive cytokine therapy based on
rIFN-γ was also evaluated in human and murine AE [43–45]. Although Th1 cytokine-mediated
therapies resulted in partial inhibition of the parasite growth in mice and in clinical stabiliza-
tion of AE in human patients, such treatments do not generate immunologic memory and may
lead to non-specific inflammation, which in turn can cause severe adverse effects.
An alternative approach, referred to as active immunotherapy, is to administer potential tar-
get antigens, and thus to elicit a specific immune response and immune memory. A high po-
tential for such therapeutic vaccines directed against various pathogens has been reported,
including rabies virus [46],Mycoplasma pulmonis [47],Mycobacterium tuberculosis [48], Leish-
mania major [49], and Schistosoma mansoni [50]. These studies demonstrated that administra-
tion of antigen doses (alone or in combination with additional chemotherapy in the case of
rabies [46] and Schistosoma [50] could clear or greatly reduce an ongoing infection by the re-
spective pathogen. It is now believed that therapeutic vaccines against chronic infectious dis-
eases may overcome the potential impairment of immune responses due to an established
infection [51]. However so far, no studies focused on creating and assessing therapeutic vac-
cines for the treatment of AE.
The P29 protein has been identified in the larval stage of both E. granulosus [52,53], and E.
multilocularis [54]. Prior studies suggested a possible role of E. granulosus P29 (EgP29) as de-
velopmentally regulated component of the E. granulosusmetacestode [55]. Vaccination of
mice with bacterially produced recombinant EgP29 (rEgP29) was shown to lead to significant
protective immunity, resulting in 96.6% protection against challenge infection with E. granulo-
sus protoscoleces [56]. In this study, we examined the antigenicity and immunogenicity of re-
combinant E.multilocularis P29 (rEmP29), and applied rEmP29 either as a vaccine
(prevention of infection) or as an active immunotherapy (treatment of infection).
Materials and Methods
Ethical statement
Female BALB/c mice, 8–10 weeks old were obtained from Charles River GmbH, Germany. All
mice were housed und handled under standard aseptic animal laboratory conditions according
to the Swiss Animal Welfare regulations (license No. Be108/08). For all experiments, animals
were matched for age and weight. Experimental groups of 6 animals each were used.
Maintenance of E.multilocularismetacestodes
The E.multilocularis isolate H95 [57] was used in this study. Metacestodes were maintained in
BALB/C mice by serial transplantation passages as previously described [58]. For experimental
infections, vesicle suspensions were prepared as described earlier [59], and mice were intraperi-
toneally (i.p.) injected with 100 μl vesicle suspension (corresponding to approximately 50
metacestodes).
Recombinant antigens
The recombinant E.multilocularis P29 (rEmP29) protein was expressed and purified as previ-
ously described. [60]. Recombinant Neospora caninummicroneme protein 1 (rNcMIC1), used
here as an irrelevant control antigen expressed and purified under identical conditions, was
produced as previously described [61]. Purified rEmP29 and rNcMIC1 were dialysed against
rEmP29 for Prevention and Immunotherapy of AE
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PBS for two days at 4°C and kept at -80°C for subsequent use in serological assays. Prior to the
use in cell cultures or mouse experiments, recombinant antigens were purified by affinity chro-
matography employing a Detoxi-gel affinity pack column (Pierce, Rockford, IL USA) to re-
move endotoxins. Protein concentration was determined by the Bio-Rad Bradford protein
assay (Bio-Rad Laboratories GmbH, Germany). No measurable endotoxins were detected
using Pierce LAL Chromogenic Endotoxin Quantitation test (Thermo Scientific, Rockford, IL,
USA) conducted according to the manufacturer's protocol.
Animal experimentation
Three experiments were performed. In Experiment 1, mice were vaccinated with rEmP29 and
the immune response towards vaccination was investigated. In experiment 2, mice were vacci-
nated and then experimentally infected by intraperitoneal (i.p.) injection of E.multilocularis
vesicles to evaluate the immunoprotective potential of rEmP29 (experiment 2). In Experiment
3, mice were infected by (i.p.) injection of E.multilocularismetacestode vesicles, and animals
were treated at one month post-infection by (i.p.) injection of rEmP29 antigen in order to as-
sess the immunotherapeutic potential of rEmP29.
For the present mouse experiments, saponin was chosen as adjuvant since it appears as the
most widely used adjuvant in previous research studies on vaccination against E.multilocularis
[24] or E. granulosus [27,62]. In addition, Quillaja saponins are potent adjuvants that enhance
both cellular and humoral immune responses [63,64].
For experiment 1 (assessment of immunogenicity of rEmP29), 18 mice were divided into 3
groups. On days 1, 14, and 28, post-vaccination, all mice from group 1 (rEmP29-Sap) were i.p.
injected with 20 μg rEmP29 plus 50 μg saponin adjuvant (Sigma-Aldrich, Buchs, Switzerland),
formulated in sterile saline solution (0.09% NaCl) such as to yield a final volume of 100μl. Mice
from group 2 were administered 50 μg saponin in saline solution (adjuvants control = Sap),
and mice from group 3 received only sterile saline solution (infection control = NaCl). On day
42, all mice were euthanized, sera and spleen were collected and analysed for antibody and
cytokine responses.
For experiment 2 (assessment of immunoprotective potential of rEmP29), 24 animals were
divided into 4 groups. On days 0, 14, and 28 (Table 1), all mice from group 1 (rEmP29-Sap/
Inf) were i.p. injected with 20 μg rEmP29 plus 50 μg saponin adjuvant, formulated in sterile sa-
line solution (0.09% NaCl) in a final volume of 100μl. Mice from group 2 were administered
Table 1. Preventive immunization and immunotherapy with rEmP29 antigen against secondary AE in BALB/c mice.
Immunization Inf. Treatment Sacriﬁce/analysis
D0 D14 D28 D42 D73 D87 D101 D132
Preventive vaccination
Group 1 (rEmP29-Sap) x x x x - - - x
Group 2 (Sap) x x x x - - - x
Group 3 (NaCl) x x x x - - - x
Group 4 ((rNcMIC1-Sap) x x x x - - - x
Therapeutic vaccination
Group 1 (rEmP29-Sap) - - - x x x x x
Group 2 (Sap) - - - x x x x x
Group 3 (Sap) - - - x x x x x
Group 4 ((rNcMIC1-Sap) - - - x x x x x
D: days, Inf.: infection, sap: saponin adjuvant.
doi:10.1371/journal.pntd.0003795.t001
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50 μg saponin in saline solution (Sap/Inf = adjuvants control), and mice from group 3 received
only sterile saline solution (NaCl/Inf = infection control). In addition, another control group
(group 4) was introduced, mice of which received 100 μl saline solution containing 20 μg
rNcMIC1 plus 50 μg saponin (rNcMIC1-Sap/Inf control). Two weeks after the last immuniza-
tion, all mice were challenged by i.p. injection of 100 μL E.multilocularis vesicle suspension. At
3 months p.i., all mice were euthanized, followed by careful removal of the metacestode tissue
from the peritoneal cavity. The parasite mass was immediately determined on a Mettler AE160
scale (Mettler Toledo AG, Greifensee). Spleen and blood samples were also taken for further
analyses. Spleens were taken and placed in Hanks' balanced salt solution on ice. Blood samples
were allowed to clot at room temperature for 30 min and then were centrifuged for 10 minutes
at 3000 rpm.
For experiment 3 (assessment of immunotherapy with rEmP29), 24 mice were infected i.p.
with 100 μl E.multilocularis vesicle suspension. At 1 month post infection (p.i.), mice from
group 1 (Inf/rEmP29-Sap) were i.p. injected with 20 μg rEmP29 plus 50 μg saponin adjuvant,
emulsified in sterile saline solution (0.09% NaCl) for a final volume of 100μl. Mice from group
2 were administered 50 μg saponin in saline solution (Inf/Sap = adjuvants control), mice from
group 3 received only sterile saline solution (Inf/NaCl = infection control), and mice from
group 4 were treated with 100 μl saline solution containing 20 μg rNcMIC1 plus 50 μg saponin
(Inf/rNcMIC1-Sap-control = irrelevant antigen control). These treatments were repeated 14
and 28 days later (days 87and 101, p.i., Table 1). At 3 months p.i., mice were euthanized and
parasite mass was assessed as in experiment 2. Spleen and blood samples were also collected for
further analyses, as described below. Infections, euthanasia and sample collection time points
were synchronized between mouse experiment 2 and 3 (Table 1).
An additional control group (non-infected) consisted of 6 female mice, animals were main-
tained in the same conditions till the end as outlined for experiments 2 and 3. This control
group was also sacrificed and blood and spleens were taken for the same further analyses.
Lymphocyte proliferation assay
For experiment 1 (see above), spleen cells were collected by mincing spleen tissue and passing
it through sterile 40μm-mesh stainless steel sieves. Erythrocytes were depleted using red blood
cell lysis solution (Miltenyi Biotec, Germany) for 10 minutes, and the residual spleen cells con-
taining amongst others T-cells, dendritic cells, B-cells and macrophages, were then suspended
in RPMI 1640 complete culture medium, (Gibco BRL, Basel, Switzerland) including 10% heat-
inactivated fetal calf serum (FCS; Biochrom, Berlin, Germany), 0.05 mM 2-mercaptoethanol
(Sigma-Aldrich, Buchs, Switzerland), 2 mM L-glutamine (GibcoBRL), and 100 U of penicillin
plus 50 mg of streptomycin per ml (GibcoBRL). Cell suspensions were distributed in polysty-
rene 96-well flat bottom sterile plastic plates (Greiner Bio-One; HuberLab, Aesch, Switzerland)
at 2×105 cells/100μl/well, and spleen cells were stimulated with rEmP29 at 0.1μg/2μL/well
(1 μg/mL). Wells containing cell suspensions that were left unstimulated or stimulated with
Conavalin (Con A triggers T- lymphocyte proliferation [65] (Sigma-Aldrich, Buchs, Switzer-
land) with a concentration of 0.2 μg/μL/well 2 μg/mL were included as negative control and as
an internal positive stimulation control, respectively. Experiments were performed in tripli-
cates and cultures were maintained in a 37°C humidified chamber containing 5% CO2 for 72
hours. Spleen cells proliferation was assessed using the BrdU Cell Proliferation Assay kit (Cal-
biochem, Weidenmattweg, Switzerland) according to manufacturer's protocol.
In experiment 2 and 3 (see above), spleen cells were identically isolated, and single cell sus-
pensions were either left unstimulated (maintenance in culture medium) or they were stimulat-
ed with Con A (2 μg/mL) and assessed using the BrdU Cell Proliferation Assay kit.
rEmP29 for Prevention and Immunotherapy of AE
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All experiments were performed in triplicates and the proliferative response was expressed
as a stimulation index (SI) calculated using the equation: SI = median absorbance of cells stim-
ulated with Con A or rEmP29/median absorbance of unstimulated cells.
ELISA
Serum levels of rEmP29 antigen-specific IgG, IgG1, IgG2a antibodies induced by vaccination
in experiment 1 were measured by direct rEmP29-ELISA. IgG1 and IgG2a antibody concentra-
tions were used as markers of Th2 and Th1 immune responses, respectively. Serum IgG con-
centrations against rEmP29 and Em2(G11) in mice from experiments 2 and 3 were determined
by ELISA as previously described [66]. Briefly, antigens were coated onto 96-well microplates
at a concentration of 1μg/mL for rEmP29 and 0.57μg/mL of carbohydrate for Em2 (G11)-anti-
gen [66]. Plates were incubated at 4°C for overnight. After three washes with washing buffer
(1.5 mM KH2PO4, 10 mMNa2HPO4, 150 mMNaCl, 2.5 mM KCl, pH 7.4), the plates were
blocked with blocking solution (washing buffer supplemented with 1% horse serum) for
30 min at 37°C and subsequently incubated with the mouse sera diluted at 1:100 in blocking
buffer for 30 min at 37°C. AP-conjugated goat anti-mouse IgG, IgG1 or IgG2a (Sigma-Aldrich,
Buchs, Switzerland) were used as the secondary antibody to detect bound antibodies. Finally,
immune complexes were revealed by incubating with orthophenylene diamine (Sigma-Aldrich,
Buchs, Switzerland) and 0.15% H2O2 for 30 min. The reaction was stopped by addition of
50 μL of 1 M NaOH to each well, and the absorbance at 405 nm was measured with a Microrea-
der (model 550, Bio-Rad). All samples were run in triplicates.
Quantitation of cytokine mRNA of IL-4, IL-2, IL-10 and IFN-γ by real-time
RT-PCR
For experiments 1, 2 and 3, total RNA was prepared from approximately 30 mg of mouse
spleen tissue, which was disrupted and homogenized using a FastPrep-24 homogenizer and
lysic matrix tubes (both MP Biomedicals, Illkirch Cedex, France). RNA was isolated using the
RNeasy mini kit with on-column DNA digestion (Qiagen, Basel. Switzerland), according to the
manufacturer’s instructions. RNA purity and quantity were calculated using the Nanodrop
1000 spectrophotometer. Equal amounts of six RNA samples derived from mice of the same
group were pooled. The cDNA synthesis was performed with 1μg total RNA using M-MLV Re-
verse Transcriptase RNase HMinus (Promega, Zurich, Switzerland) according to the manufac-
turer’s instructions.
Comparative quantification of IL-4, IL-2, IL-10, and IFN-γmRNA in murine spleens was
performed by real time PCR using β-actin as housekeeping gene for the qRT-PCR. Primers
were purchased from Sigma-Genosys and are all described in Table 2. Real-time PCRs were
performed using FastStart Essential DNA Green Master Kit (Roche, Rotkreuz, Switzerland),
and 2 μL of diluted cDNA in the presence of 0.2 μM of each specific primer. Quantitative PCR
was performed using the Rotor-Gene 6000 (Corbett Life Science). Samples (including cytokines
and β-actin) were run in triplicates. The programme included a hold at 95°C for 15 min, 50 cy-
cles each of denaturation at 95°C for 15 s, annealing at 55°C for 30 s, extension at 72°C for 30 s.
Melting curves were generated by heating the samples from 50°C to 90°C.
Statistical methods
Normality of distribution was checked with Shapiro-Wilk test in the software R version 3.0.1
(R core team, A Language and Environment for Statistical Computing, R Foundation for Statis-
tical Computing, Vienna, 2013). One-way analysis of variance (ANOVA) was applied for com-
parisons of the parasite load among mouse groups followed by Bonferroni-adjusted P values
rEmP29 for Prevention and Immunotherapy of AE
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003795 June 8, 2015 7 / 22
calculated by Pairwise T-Test in R. A P-value of<0.05 was considered significant. Data was vi-
sualized by boxplot in Microsoft Office Excel 2010.
For the spleen cell proliferation assay, ELISA and cytokines expression, data were expressed
as median ± standard error (S.E.) and examined for statistical significance with the Student's t-
test. P-values of less than 0.05 were considered to be statistically significant.
Results
Immunological hallmarks of vaccination with rEmP29 in mice
To determine the antibody responses and the subclass distribution of serum IgG antibody in
mice immunized with rEmP29, serum levels of IgG, IgG2a and IgG1 were analysed. As shown
in Fig 1, intraperitoneal immunization of mice with rEmP29 in combination with saponin re-
sulted in a respectively specific anti-rEmP29 IgG antibody production. Furthermore, both test-
ed IgG subclasses (IgG1 and IgG2α) were induced in rEmP29-Sap-immunized mice, with the
IgG2a median OD value being significantly higher than that of IgG1 (P<0.001).
To examine the cellular immune response elicited by the rEmP29 vaccination, spleen cells
proliferation was studied in vitro (Fig 2). In response to the rEmP29 specific antigen
Table 2. Primers used for quantitative PCR.
GenBank Target gene Accession Number Primer sequence (5‘-3‘) Product length (bp) Ref *
β-actin NM_007393 F:AACTCCATCATGAAGTGTGA 248 [36,90]
R:ACTCCTGCTTGCTGATCCAC
IFN-γ K00083.1 F:ACTCAAGTGGCATAGATGTGGAAG 167 [36,90]
R: GACGCTTATGTTGTTGCTGATGG
IL-10 NM_010548.2 F:GGTTGCCAAGCCTTATCGGA 191 [36,90]
R:ACCTGCTCCACTGCCTTGCT
IL-2 BC116845.1 F:CCTGAGCAGGATGGAGAATTACA 141 [36,90]
R:TCCAGAACATGCCGCAGAG
*Citations between brackets indicate the source of primers sequences.
doi:10.1371/journal.pntd.0003795.t002
Fig 1. IgG isotype antibody responses in mice vaccinated i.p. with rEmP29 and saponin adjuvant.
Antigen-specific ELISA was performed with sera collected 6 weeks after the first immunization. IgG, IgG1 and
IgG2α results refer to median A404nm values + standard error (SE).
doi:10.1371/journal.pntd.0003795.g001
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stimulation, spleen cells from rEmP29-vaccinated mice exhibited a significantly higher prolif-
eration rate when compared to spleen cells from mice treated with saponin (P = 0.002) or saline
solution (P = 0.006). Spleen cells from all animals responded to the polyclonal stimulant Con A
as a positive proliferation control (Fig 2). Thus, priming with the rEmP29 vaccine led to specif-
ic proliferation of spleen cells, suggesting subsequent expansion of antigen-specific T cells.
To characterize the cytokine expression profile in response to recombinant rEmP29 vacci-
nation, we examined the mRNA levels of IFN-γ, IL-2, IL-4 and IL-10 in spleen cells by real-
time RT-PCR. As shown in Fig 3A and 3B, immunization of mice with rEmP29 or with adju-
vants alone (Sap) resulted in a significantly higher IL-4 (P< 0.001) and IFN-γ (P< 0.001)
mRNA expression level when compared to spleens from saline-treated mice (NaCl) (Fig 3A
and 3B).
IL-2 mRNA expression in spleen cells from mice immunized with rEmP29-Sap or saponin
alone was significantly higher (P< 0.001) than that one observed in the control non-immu-
nized animals (NaCl group) (Fig 3C). Similarly, IL-10 mRNA-level was significantly higher
in rEmP29-Sap- and Sap-vaccinated mice when compared to the mouse group receiving only
saline solution (NaCl group). However, the magnitude of IL-10 and IL-2 mRNA levels rising
in rEmP29-Sap-immunized mice was lower than in mice inoculated with adjuvants alone
(Fig 3D).
Vaccination with rEmP29 antigen results in reduced parasite burdens in
mice experimentally challenged with E.multilocularismetacestodes
Recombinant EmP29 antigen was evaluated as a vaccine against E.multilocularis in the murine
model of secondary AE (Fig 4A, Immunization and then infection). The efficacy was assessed
by monitoring the parasite burden in the peritoneal cavity. In non-vaccinated saline treated
mice, experimental infection resulted in a median parasite weight of 10.66 ± 1.68 g, while
Fig 2. Measurement of spleen cell proliferation after mitogenic or antigen-specific stimulation of mice immunized with rEmP29 antigen. Two weeks
after the final immunization, pooled spleen cells from the different immunized groups were cultured and stimulated separately with rEmP29 antigen (1 μg/mL)
or with ConA (2 μg/mL), and proliferation levels were subsequently measured.
doi:10.1371/journal.pntd.0003795.g002
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saponin treatment (6.57 ± 2.18 g) and vaccination with rNcMIC1 (10.70 ± 4.03 g) had no sig-
nificant impact. In contrast, vaccination of mice by rEmP29 resulted in a significantly reduced
median parasite bio-mass (2.68 ± 2.08 g), which was 75%, 59% and 75% lower when compared
to NcMIC1-vaccinated, saponin-treated, or saline treated groups, respectively (Fig 4A).
Immunotherapy with rEmP29 antigen in mice experimentally infected
with E.multilocularismetacestodes results in reduced parasite burdens
To determine whether the course of an already established secondary E.multilocularis infection
in mice could be altered by immune stimulation with rEmP29 antigen, three doses of rEmP29
formulated in saponin adjuvants were administered during the early phase of (after 1 month)
(Fig 4B, Infection and then immunization). Mice that were infected and received only the saline
solution developed a high median parasite load (5.37 ± 2.72 g). Similarly, mice that were treat-
ed with the adjuvant alone also developed high infection intensities (4.9± 2.31 g). Mice treated
with rNcMIC1 antigen emulsified in saponin showed the highest median parasite burden
(6.95 ± 3.81 g). In contrast, mice that were treated with three injections of rEmP29-saponin
formulation on days 73, 87 and 101 (Table 1) post-infection exhibited a significantly lower par-
asite load (2.51± 2.07 g). In two mice the parasite loads (0.13 and 1.08 g) were largely inferior
to the median. Thus immunotherapy with rEmP29 resulted in a reduction of the median meta-
cestode weight of 53%, 49% and 64%, as compared to the NaCl-, saponin- and rNcMIC1-sapo-
nin-treated control mice, respectively. These differences were significant only upon
comparison of rEmP29 and rNcMIC1 treated groups.
Fig 3. Relative mRNA expression levels of IL-4 (A), IFN-γ (A), IL-2 (C) and IL-10 (D) in spleens from BALB/Cmice, following immunization with
rEmP29 (rEmP29-sap) or with adjuvant alone (sap). The IL-4/IFN-γ cytokine mRNA ratios were calculated from the three groups (B) and indicate a
Th2-dominated response in rEmP29-sap and sap-alone-treated mice compared to none immunized mice.
doi:10.1371/journal.pntd.0003795.g003
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Fig 4. Therapeutic and protective effect of rEmP29 against secondary AE infection in BALB/c mice.
(A) Assessment of parasite load in the intraperitoneal cavity of mice vaccinated i.p. with rEmP29-saponin,
rNcMIC1-saponin or adjuvant alone and subsequently infected with E.multilocularis vesicle suspension.
Mice were vaccinated three times (2 weeks apart), and at 3 months p.i. mice were euthanized and the total
parasite mass recovered and weighed. (B) Assessment of parasite load in post-infection treated mice with
rEmP29-saponin, rNcMIC1-saponin or adjuvant alone. Treatment started at 1 month after initial secondary
infection. Shapiro-Wilk test suggested that the measured cyst weights followed normal distribution in all
mouse groups. One-way ANOVA analysis proved a significant difference between the animal groups from
experiment no. 2 (immunization before infection (A). Post-Hoc analysis by Pairwise T-Test with Bonferroni-
adjustment showed that there was a significant reduction of the median parasite weight in rEmP29-Sap
immunized group (A). For experiment no. 3 (B), significance was found only between rEmP29-Sap- and
rNcMIC1-Sap-treated groups.
doi:10.1371/journal.pntd.0003795.g004
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Analysis of E.multilocularis-specific IgG antibodies responses to
vaccination and immunotherapy in infected mice
In order to characterize humoral immune responses, sera of the different experimental groups
in experiments 2 and 3were analysed by rEmP29 ELISA. All samples from E.multilocularis in-
fected mice contained antibodies directed against rEmP29 protein, and the significantly highest
anti-rEmP29 IgG-levels were detected in those animals that had been vaccinated with
rEmP29-antigen and in mice that were treated with rEmP29 after being infected (Fig 5).
As shown in Fig 5, serum levels of the specific IgG response against the Em2 (G11) antigen
was significantly lower in rEmP29 vaccinated mice, when compared to the corresponding
groups immunized with saline solution only, saponin alone or with rNcMIC1-saponin.
Similarly, anti-Em2(G11)-specific IgG antibody levels in infected mice that were treated
with rEmP29 were inferior to those in infected and treated animals with rNcMIC1 or left un-
treated. However, animals treated with saponin alone showed similar levels of anti-Em2 (G11)-
specific IgG as compared to rEmP29-sap treated mice.
Effects of EmP29-vaccination and immunotherapy on spleen cell
proliferation and cytokine expression in experimentally infected mice
The proliferative response of spleen cells to ConA-mitogen is an important overall indicator of
immune fitness. The proliferative responses of spleen cells to ConA stimulation from all groups
(experiments 2 and 3 and including non-infected mouse group) are presented in Fig 6, by
using the value of 100% as a reference proliferation of spleen cells (derived from non-infected
mice). The proliferation indices of spleen cells from the four infected mouse groups of experi-
ment no. 2; NaCl/Inf, Sap/Inf, rNcMIC1-Sap/Inf and rEmP29-Sap/Inf were 41%, 32%, 30%
Fig 5. Serological analyses. Antibody responses of i.p. infected mice, vaccinated pre- or post-parasite challenge, were measured by ELISA using affinity-
purified Em2 (G11) and rEmP29 antigen. Bars indicate SE. Immunization and then infection: mouse groups from experiment no. 2 were immunized with
different preparations (Saline solution (NaCl), saponin (Sap), rEmP29 plus saponin (rEmP29-Sap) or with rNcMIC1 plus saponin (rNcMIC1-Sap)), and then
challenged by infection with an E.multilocularismetacestode suspension. Infection and then immunization: mice from experiment no. 3 were infected with E.
multilocularismetacestode suspension, and at 1 month p.i., animals were treated with different preparations (physiological saline solution (NaCl), saponin
(Sap), rEmP29 plus saponin (rEmP29-Sap) or with rNcMIC1 plus saponin (rNcMIC1-Sap)).
doi:10.1371/journal.pntd.0003795.g005
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and 47%, respectively and were thus considerably (P< 0.001) lower than those observed in
non-infected control groups (100%) (Fig 6).
In mouse experiment no. 3, spleen cell proliferation rates triggered by ConA were signifi-
cantly (P< 0.001) reduced (44%, 50% and 41% in Inf/NaCl, Inf/rNcMIC1-Sap and Inf/
rEmP29-Sap mouse groups, respectively). However, the proliferation of spleen cells in infected
animals that were treated with saponin alone was similar (97%) to the non-infected control
group (100%) (Fig 6).
The cytokine expression profiles in response to recombinant rEmP29 vaccination were in-
vestigated by comparing IFN-γ, IL-2, IL-4 and IL-10 mRNA levels in the spleen of the different
treatment groups with cytokine mRNA levels in non-infected control mice by real time
RT-PCR (Fig 7).
Significantly higher levels of IL-4 mRNA expression were detected in all 8 groups from ex-
periments nos. 2 and 3, when compared to non-infected mice (Fig 7A).
In terms of IFN-γ expression, in rEmP29- vaccinated or-treated mice, IFN-γmRNA levels
were significantly elevated when compared to the corresponding groups treated with saline
only (NaCl/Inf and Inf/NaCl groups) (Fig 7B). In addition, saline-treated mice in infected ani-
mals exhibited similar levels of splenic IFN-γmRNA expression as non-infected mice (Fig 7B).
Furthermore, the IL-4 to IFN-γmRNA expression ratio was calculated for each animal
group and displayed as a graph (Fig 7C). Transcription of IL-4 mRNA in spleen cells from
Fig 6. The proliferative responses to ConA stimulation of pooled spleen cells from non-infected control mice and from AE-infected mice
(vaccinated with rEmP29 antigen and subsequently infected, or immunized with rEmP29 antigen at 1 month p.i.) were determined at 3 months p.i..
Stimulation indices (SI) were calculated as median ratio of A404nm values of the stimulated cells divided by values of untreated cells. The SI value obtained
from non-infected mice was taken as 100% and SIs of other experimental groups were calculated in percentage to non-infected mice.(**), a statistically
significant difference was found between non-infected mice and all remaining groups, except Inf/Sap. Immunization and then infection: mouse groups from
experiment no. 2 were immunized with different preparations (saline solution (NaCl), saponin (Sap), rEmP29 plus saponin (rEmP29-Sap) or with rNcMIC1
plus saponin (rNcMIC1-Sap)), and then challenged by infection with E.multilocularismetacestode suspension. Infection and then immunization: mice from
experiment no. 3 were infected with E.multilocularismetacestode suspension, and at 1 month p.i., animals were treated with different preparations (saline
solution (NaCl), saponin (Sap), rEmP29 plus saponin (rEmP29-Sap) or with rNcMIC1 plus saponin (rNcMIC1-Sap)).
doi:10.1371/journal.pntd.0003795.g006
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secondary AE-infected mice (NaCl/Inf and Inf/NaCl) was 16 times higher than that of IFN-γ
(Fig 7C). In infected BALB/c mice that were vaccinated (rEmP29-Sap/Inf) or treated (Inf/
rEmP29-Sap) with rEmP29, the ratio of IL-4/IFN-γmRNA was lower than those of different
control groups from experiments no. 2 and 3 (NaCl/Inf, Sap/Inf, rNcMIC1-Sap/Inf, Inf/NaCl,
Inf/rNcMIC1-Sap). Nevertheless, treatment of infected mice with saponin (Inf/Sap) alone re-
sulted in a similar IL-4/IFN-γmRNA-ratio as found in animals that received rEmP29-Sap at 1
month post-infection.
In experiment no. 2, as shown in Fig 7D, infected mice (NaCl/Inf and Inf/NaCl) had signifi-
cantly higher IL-10 mRNA expression levels than controls (non-infected) (P< 0.001). In addi-
tion (Fig 7D), IL-10 mRNA transcription levels were significantly lower in rEmP29 vaccinated
and infected mice (rEmP29-Sap/Inf), when compared to the following groups: NaCl/Inf, Sap/
Inf and rNcMIC1-Sap/Inf. Similarly, immunotherapy treatment (experiment no. 3) of infected
mice with rEmP29 in conjunction with the saponin adjuvant resulted in significantly reduced
IL-10 transcription levels when compared to different control groups: Inf/NaCl, Inf/Sap and
Inf/rNcMIC1-Sap (Fig 7D). The highest transcription level of IL-10 mRNA was observed in
spleen cells from rNcMIC1-sap vaccinated mice (rNcMIC1-Sap/Inf group).
All infected groups (experiment nos. 2 and 3) presented significantly higher expression lev-
els of IL-2 mRNA when compared to controls (non-infected) (Fig 7E). Infected mice that were
immunized (experiment no. 2) or treated (experiment no. 3) with rEmP29 displayed a signifi-
cantly lower amount of mRNA coding for IL-2, correspondingly compared to the following
groups: only infected mice (NaCl/Inf and Inf/NaCl), infected mice that were either immunized
or treated with adjuvant (Sap/Inf and Inf/Sap) or immunized with rNcMIC1-saponin
(rNcMIC1-Sap/Inf group) as shown in Fig 7E.
Discussion
This is the first study describing an antigen-based immunotherapy for experimentally induced
secondary murine AE, based on the bacterially produced recombinant rEmP29 antigen. We
also present data that demonstrates an explorative experiment tackling the efficacy of rEmP29
antigen as a vaccine candidate against experimental (secondary) E.multilocularis infection in
mice. In addition, spleen cells recall-responses upon antigen stimulation and real time PCR-
based cytokine mRNA expression analyses suggested that both, vaccination and immunothera-
py, overrode to some extent the Echinococcus-mediated immunomodulation at the host-para-
site interface. EmP29 was selected as a target antigen for two reasons: (i) EmP29 exhibits high
expression levels in both E.multilocularis [54] and E. granulosus [52,53] metacestodes, indeed
it was previously suggested that P29 could have an important role in developmental regulation
of the E. granulosusmetacestode [55]; (ii) recombinantly expressed E. granulosus P29 (rEgP29)
vaccination provides effective protection of mice against challenge infection with E. granulosus
protoscoleces [56].
Three injections of rEmP29-antigen formulated in saponin adjuvants prior to experimental
infection lead to a significantly reduced (75%) parasite mass formation as compared to non-
vaccinated control mice. In addition, intraperitoneal injection of rEmP29 antigen during the
Fig 7. Cytokine gene expression levels of murine spleen cells following vaccination with rEmP29 in pre- (Immunization and then infection) or post-
infection (Infection and then immunization) (A) Interleukin (IL)-4, (B) interferon (IFN)- γ, (C) IL-4/IFN-γmARN ratios (D) IL-10 and (E) IL-2. Bars
represent SE. Immunization and then infection: mouse groups from experiment no. 2 were immunized with different preparations (saline solution (NaCl),
saponin (Sap), rEmP29 plus saponin (rEmP29-Sap) or with rNcMIC1 plus saponin (rNcMIC1-Sap)), and then challenged by infection with E.multilocularis
metacestode suspension. Infection and then immunization: mice from experiment no. 3 were infected with E.multilocularismetacestode suspension and, at
1 month p.i., animals were treated with different preparations (saline solution (NaCl), saponin (Sap), rEmP29 plus saponin (rEmP29-Sap) or with rNcMIC1
plus saponin (rNcMIC1-Sap)).
doi:10.1371/journal.pntd.0003795.g007
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chronic phase of AE resulted in a partial control of parasite growth, and yielded a reduced the
median parasite mass by 53% as compared to non-treated mice.
In contrast to the result obtained in our study, with rEmP29 applied as preventive vaccine
against secondary AE, immunization of mice with the recombinant Em14-3-3 (E14t) in combi-
nation with a saponin adjuvans, did not show any reduction in the parasite load when com-
pared to non-vaccinated animals [24]. This discrepancy between rEmP29 and E14t cannot yet
be explained, but hypothetically the effect may be related to distinct biological function or by
different antigenic and immunogenic properties of the reagents.
So far, the core biological function of EmP29 in the Echinococcus biology is still unresolved.
An NCBI BLAST search showed that the amino acid sequence of EmP29 (GenBank, accession
no. AAD53328.1) exhibited 100% homology to E. granulosus endophilin B (GenBank, acces-
sion no. CDJ21798.1) [18]. However, EmP29 shares only a low degree of identity (22%) with
human endophilin B1 (S1 Fig). In eukaryotes, endophilin B1 is essential for synaptic transmis-
sion [67], and inhibition of its expression has been shown to produce profound defects in syn-
aptic vesicle endocytosis [68]. However, the mechanism by which endophilin B promotes
endocytosis has remained controversial. Therefore, the future functional characterization of
EmP29 will be of great interest to understand the cellular pathways and functional activities as-
sociated with EmP29.
To induce experimentally murine secondary AE, E.multilocularismetacestodes are injected
intraperitoneally into susceptible mice. Thus at the starting point of an experimental immuno-
therapy (one month p.i.), it is conceivable that metacestodes are already well established within
the host, including a solid protection by the parasite-derived laminated layer [69,70]. In our ex-
periments, the third and final injection of rEmP29 antigen was administered at 1 month before
the end of the experiment. Thus, we do not know yet how the parasite growth-potential devel-
ops at later time points. Therefore, further animal studies are planned, during which different
experimental starting- and end-points will be assessed. We hypothesize that the effectiveness of
immunotherapy is largely dependent on the time point of the initiation of treatment in relation
to the infection stage. For example in pythiosis in horses, caused by Pythium insidiosum, a suc-
cessful immunotherapy depends on the chronicity of the lesions prior to immunotreatment.
Therefore, all horses with lesions less than 15 days old were cured by an early P. insidiosum-an-
tigen, while those with chronic pythiosis (more than 2 months duration) eventually died
[71,72]. Other important parameters also require further assessment, such as antigen dosages,
adjuvants, frequency of applications and inoculation routes, all of which would lead to an opti-
mization of the immunotherapeutic potential of rEmP29 antigen as exploratively documented
in the present study. In a similar line of plans, a future evaluation of the immunotherapeutic
and immunoprotective potentials of rEmP29 will have to focus on the primary egg infection
model that mimics the natural infection in humans more properly.
In human AE, specific IgG antibody levels against Em2(G11) and recEm18 correlate to
some extent with the clinical status of the patient [66,73]. In our study, we found that IgG con-
centrations against Em2(G11) were significantly lower in rEmP29 vaccinated mice in the pre-
or post- infection status, when compared to the corresponding control mouse groups immu-
nized or treated with saline solution, saponin alone or with mice that were immunized with
rNcMIC1-saponin before challenge.
In our study, administration of adjuvant alone prior to the infection, resulted in a non-spe-
cific but still significant (P = 0.002) reduction of the median parasite weight of 38% when com-
pared to mouse groups that received only saline solution. It was reported in a previous study
that administration of saponin alone also gave a limited non-specific protection against sec-
ondary AE in mice. Similarly, other adjuvants such as CpG oligodeoxynucleotides [30] (CpG
ODN), Freund’s complete/Incomplete adjuvants (CFA/IFA) [30], Gerbu [74] or cholera toxin
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subunit B (CTB) [75] have also been shown to exhibit non-specific protection against larval or
adult stages of E.multilocularis.
In our study, non-specific and significant protection against secondary AE with saponin
alone was observed when mice were treated before (pre-infection treatment; exp.2) but not
after the infection (post-infection treatment; exp.3). In the same line, it was shown that prophy-
lactic treatment of cotton rat (Sigmodon hispidus) with BCG (Bacillus Calmette-Guerin) en-
tirely and non-specifically inhibited the establishment of E.multilocularismetacestodes in the
intraperitoneal cavity [76,77], however, application of BCG at two weeks post-infection did not
limit the development and the proliferation of the parasite[76].
Until now there is no accurate scientific explanation for this phenomenon, however, in ad-
dition to the fact that adjuvants generally increase host immunity against infectious diseases,
one reason for such a non-specific protection phenomenon may be that saponin or other adju-
vants display a direct effect on E.multilocularismetacestodes or adult worms.
In the present study, we found that the IL-4/IFN-γmRNA ratios in the spleen of vaccinated
mice, or animals treated with rEmP29 saponin formulations, were lower than in spleens of
mice treated with saline (infection controls). In addition, corresponding IL-10 and IL-2 expres-
sion levels were lower in vaccinated and treated mice compared to saline-treated mice. Thus,
higher levels of IFN-γ and reduced expression of IL-10 and IL-2 mRNAmight be associated
with reduced growth of the parasite in vaccinated and treated mice, and a Th1-oriented re-
sponse could contribute to the restricted parasite growth of E.multilocularis within its interme-
diate host. This is supported by elderly published data where the essential role of cellular
immunity in controlling E.multilocularis infection in humans as well as in mice was confirmed
[31,32].
In AE, CD4 (+) CD25 (+) regulatory T cells, have been studied intensively since they are the
main IL-10 secreting cells [78,79] and their deficiency abrogates parasite-tolerance. Accumu-
lating evidence from correspondingly selected knockout mice suggested that IL-2 is crucial for
the homeostasis and function of CD4 (+) CD25 (+) regulatory T cells in vivo [79–85]. This syn-
ergic functional relationship between IL-10 and IL-2 may explain the simultaneous down regu-
lation of mRNA levels of both cytokines observed in our study.
The recombinantly expressed rNcMIC1 was used as negative control, since no homologue
was found in E.multilocularis [18]. Recombinant NcMIC1was produced and purified under
the same conditions as rEmP29. The antigenic but not the immunosuppressive properties of
NcMIC1 were reported [61], but since our results revealed that rNcMIC1 harbors a significant
immunomodulatory activity by enhancing IL-10 production; we do not recommend its usage
as irrelevant control for future research on Echinococcus immunology studies.
To compare the activity level of the immune system between infected mice (independently
of the vaccination or immunotherapy status) and non-infected animals, we measured the pro-
liferative activity of spleen cells in response to the mitogen ConA. In line with findings on E.
multilocularis [31,86] and E. granulosus [87] reported earlier, spleen cells of all infected groups
exhibited a significantly decreased responsiveness compared to cells from non-infected mice.
Spleen cells from E.multilocularis-infected mice treated with saponin at 1 month p.i. exhib-
ited a full responsiveness to ConA-stimulation (99%). Conversely, spleen cells from mice re-
ceiving i.p. injection of saponin prior to infection showed a significantly reduced proliferation
activity of 32% when compared to non-infected mice. We conclude that the administration of
saponin prior to infection had an immuno-stimulating activity by itself, but that this activity
was subsequently abolished by the strong immunosuppressive response mediated by the para-
site at 3 months p.i.. Upon saponin administration starting at 1 month p.i., the immunosup-
pression exerted by E.multilocularis on the host immune system was most likely still moderate,
and could not overcome the adjuvant effect. It was previously shown that saponin significantly
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promoted the ConA, lipopolysaccharide [88] and phytohemagglutinin [89] induced spleen
cells proliferation.
In conclusion, we showed that both, vaccination and active immunotherapy employing
rEmP29 antigen had a significant inhibitory effect on secondary infection with E.multilocularis
metacestodes in mice, and yielded thus a reduced parasite infection intensity when compared
mock-treated control animals. Further studies will aim to assess alternative antigens and also
other classes of adjuvants that could improve the immunotherapeutical potential of rEmP29.
Furthermore, as vaccination provided partial protection against secondary infection, it will be
important now to assess the protection mediated by rEmP29 against primary egg infection.
Supporting Information
S1 Fig. Multiple amino acid sequence alignment of Endophilin B1 (EndB1) proteins. Se-
quence alignment of E. granulosus P29 (EgP29), E. granulosus Endophilin B1 (Eg-EndB1), E.
granulosus Endophilin B1 (Eg-EndB1), E.multilocularis Endophilin B1 (Em-EndB1),Homo sa-
piens Endophilin B1 isoform 2 (H. s-EndB1-Iso2) andHomo sapiens Endophilin B1 isoform 1
(H. s-EndB1-Iso1). The GenBank accession numbers of endophilins are shown in brackets.
Strictly conserved residues among the six proteins are highlighted with black boxes. The EgP29
is 238 amino acids in length, and shares 53 (22%) identical amino acid residues with human
Endophilin B1 (isoform 1 and 2).
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